Navigation Links
Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
Date:12/9/2013

NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 24th Annual Oppenheimer Healthcare Conference in New York from December 10th through 11th, 2013. Dr. Dave will present a corporate update on Wednesday, December 11, 2013 at 8:20 am Eastern.

Presentation Information:

Date:               Wednesday, December 11, 2013
Time:               8:20 am Eastern
Location:         Crowne Plaza Hotel, New York, NY
Webcast:        http://www.veracast.com/webcasts/opco/healthcare2013/24202378549.cfm  

A live webcast of the presentation will be available via the "Investor Relations" event page of the Actinium website, www.actiniumpharmaceuticals.com. A replay of the webcast will also be archived on Actinium's website for 90 days following the presentation.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contacts:

Media and Investors:
Actinium Pharmaceuticals, Inc.
Corey Sohmer
Phone: (646) 459-4201
E-mail: csohmer@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
3. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
6. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
7. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
8. Actinium Pharmaceuticals Announces New Round of Financing
9. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  A recent study at Shriners Hospitals for ... in the country dedicated to the treatment of pediatric ... that the Surfacide Helios ® UV-C Disinfection System ... bacterial pathogens not killed by the EVS (manual) cleaning ... American Burn Association,s 49th Annual Meeting in ...
(Date:3/27/2017)... IRVINE, Calif. , March 27, 2017  Cryoport, ... announced that it intends to offer shares of common ... shelf registration statement on file with the Securities and ... market and other conditions, and there can be no ... be completed, or as to the actual size or ...
(Date:3/27/2017)... , March 27, 2017 ... attendees and more than 600 exhibitors from 70 ... opportunities and solutions that will advance the medical ... 2017 at the Messe Stuttgart, Stuttgart, ... medical technology platform showcasing the key trends and ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... , ... The Case Management Society of America (CMSA) will install six new ... membership has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on ... Advisory position has also been added to the BOD, per an appointment made by ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... Foothill Ranch, California (PRWEB) , ... March 27, 2017 , ... ... company’s commitment to its customers. First National Capital has added 10 new sales professionals ... to grow its sales positions by 15 additional new hires over the course of ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce the ... subjects. The ELITE DXA has an active scan window, which is more than double ... fit in the scan area could not undergo an accurate total body bone density or ...
Breaking Medicine News(10 mins):